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Background.Themortality from all malignant and nonmalignant asbestos-related diseases remains unknown.The authors assessed
the incidence and risk factors for all asbestos-related deaths. Methods. The sample included 544 patients from an asbestos-
exposed community in the area of Barcelona (Spain), between Jan 1, 1970, and Dec 31, 2006. Competing risk regression through a
subdistribution hazard analysis was used to estimate risk factors for the outcomes. Results. Asbestos-related deaths were observed
in 167 (30.7%) patients and 57.5% of these deaths were caused by some type of mesothelioma.The incidence rate after diagnosis was
3,600 per 100,000 person-years. In 7.5% of patients death was non-asbestos-related, while pleural and peritonealmesotheliomawere
identified in 87 (16.0%) and 18 (3.3%) patients, respectively. Conclusions. Age, sex, household exposure, cumulative nonmalignant
asbestos-related disease, and single malignant pathology were identified as risk factors for asbestos-related death. These findings
suggest the need to develop a preventive approach to the community and to improve the clinical follow-up process of these patients.
1. Introduction
Asbestos is an established human carcinogen [1] found natu-
rally in rocks and widely used by industry [2]. The exposure
to this material occurs through the inhalation of fibres in the
ambient air in factories handling asbestos or in the indoor
air in housing and buildings containing asbestos materials
[3]. First published at the beginning of the 20th century,
its harmful effects received the ARD acronym (asbestos-
related disease) and, at the beginning of the 21st century, ARD
became a relevant public health issue [4].
According to various estimates [5, 6], Spanish imports
of this material during the 20th century were 2.6 million
MT, with a peak in 1974 (126.000MT), corresponding to a
lower consumption in more developed economies [6, 7]. In
Spain there is a lack of adequate estimates of the number of
workers exposed to asbestos and community-based registries
of ARD-affected people [6]. In this context, an important
public health issue concerns the risk of developing ARD from
environmental asbestos exposure in residents who live near
big asbestos processing plants [8–10].
Hindawi
Canadian Respiratory Journal
Volume 2017, Article ID 9015914, 9 pages
https://doi.org/10.1155/2017/9015914
2 Canadian Respiratory Journal
All types of asbestos can causemesothelioma, lung cancer
[1], and nonmalignant ARD such as asbestosis and pleural
thickness [3, 4, 9]. There is a concern about the potential
mortality of ARD due to malign mesothelioma [7, 11] and
although infrequent, it is one of the most lethal diseases
among this group of pathologies.
Consistent evidence of the harmful effects of asbestos
[2, 12, 13] and trade restrictions introduced in Europe in the
1980s onwards have contributed to its declining use in some
countries over the past decades. However, the asbestos latent
period most commonly reported of 20–40+ years from the
beginning of exposure [11, 14] means that in case of malign
pleural mesothelioma, incidence rates rose steeply until the
1990s in most European countries and the United States.This
continued increase over the past twodecades in industrialised
countries is yet to peak worldwide [2, 3, 7, 15, 16].
About 125 million workers continue to be directly
exposed to asbestos in the world [3, 17]. In 2004, asbestos-
related lung cancer, malignant pleural mesothelioma, and
asbestosis from occupational exposure have resulted globally
in more than 100,000 deaths. Although several thousands
of deaths can be attributed to other ARD or to nonoc-
cupational exposure to asbestos [3], asbestos mortality has
not been considered taking into account non-ARD death as
a competing risk. Furthermore, the overall impact on the
whole population, in terms of mortality for all forms of ARD
and particularly the benign pathology, remains understudied
[16]. Therefore, the main objective of this study is to assess
incidence and independent risk factors of mortality from all
forms of ARD with a competing risk analysis in a cohort of
primary care patients. The patients were identified from 1970
to 2006 in the region of Barcelona (Spain).
2. Materials and Methods
2.1. Design, Setting, and Study Population. This is a communi-
ty-based cohort study with catchment population of 485,578
people (2007 Census) assigned to 14 Primary Care Centers in
a low socioeconomic area (according to the Gross Domestic
Product per capita, 2012) [18] of the region of Barcelona
(Spain). A cement processing plant remained in this zone
for 90 years (1907–1997). This facility processed 14.446MT
of asbestos per year (80% white, 15% blue, and 5% brown)
which corresponds to a third of the entire volume of asbestos
imported into Spain during the 20th century [10].
Since 2003, a primary healthcare research team has
launched a public-funded research program in coordination
with the reference hospital to analyse the profile of ARD
events [19]. The detailed research protocol has been already
published [20]. The study cohort included all patients, 544,
with any ARD diagnosis identified between Jan 1st, 1970, and
Dec 31st, 2006, in the catchment area.
2.2. Asbestos Health Effects Diagnosis Criteria and Study Case
Definition. The ARD acronym group comprises 10 hetero-
geneous entities [21, 22] to describe asbestos health effects.
The malignant pathology includes pleural mesothelioma,
peritoneal mesothelioma, bronchopulmonary neoplasm, and
Table 1: International death codes for asbestos-related diseases
(ARD).
ARD event IDC-8 IDC-9 IDC-10
Pleural mesothelioma — — C450
Peritoneal mesothelioma — — C451
Unspecified mesothelioma — — C459
Malign pleural Neoplasm 1630 163 C384
Asbestosis 5152 501 J61
Pleural plaques — — J920
Unspecified pleural disease 5110 5110 J948
Unspecified fibrothorax 5110 5110 J941
Hydrothorax 5112 5118 J90
Rounded atelectasis
unspecified 5190 5180 J981
Pneumoconiosis 5159 505 J64
Chronic restricted aerial flow — — —
Note. IDC: International Disease Code.
several rare lung neoplasm. The nonmalign (benign) pathol-
ogy comprises pleural plaques, pleural thickness, pulmonary
effusions or hydrothorax, rounded atelectasis, lung fibrosis
(asbestosis), and chronic airway obstruction.
We defined ARD diagnosis criteria [21] as having the next
three clinical conditions: (a) past history of asbestos exposure
and/or a reasonable ARD latent time, (b) evidence of asbestos
exposure by clear structural damage in the lung confirmed
by rx-chest and/or evidence of asbestos bodies (identified
by bronchoalveolar lavage or cytology), and (c) exclusion
of other more prevalent diseases, such as tuberculosis. The
pathological anatomy diagnosis prevailed over clinical suspi-
cion. All diagnoses were confirmed by a general practitioner
and a specialist in respiratory medicine. All ARD deaths
were registered using the tenth International Classification of
Diseases (10th ICD) but 8th ICD and 9th ICD versions were
also required (Table 1).
2.3. Data Sources. Data were retrospectively collected from
Jan 1, 1970, until Dec 31, 2003, and prospectively collected
from this date. Before 1970, most community-based data and
clinical information available were unreliable.
Clinical information was provided by primary healthcare
and tertiary hospital medical records (morbidity, mortality,
and discharge). Face-to-face interviews with patients or their
relatives were also carried out to complete the information
and to identify the source and duration of asbestos exposure.
In case of any combined sources of exposure, the patient
was assigned to the highest exposure group according to
the following order: labor, household, and environmental. In
case of work exposure, work contracts and/or payroll were
required; in case of household exposure, a history of living
with aworker exposed to asbestos in his/her jobwas required;
and for environmental exposure, the main resident had to
be located within the study area. The length of occupational
exposure to asbestos was confirmed with work contracts
and/or available payroll. The onset of exposure for each
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patient was identified when the patient started working in the
factory, coexisting with a worker or living in the study area.
2.4. OutcomeVariable. Theprimary outcomewas considered
ARD-related death, death due to ARD, confirmed with the
official mortality registry data bank in all cases. Moreover, all
our deathswere linkedwith this register, and the concordance
rate between our underlying cause of death and the mortality
registry was 97.5%.
2.5. Covariates. The following categorical covariates were
considered: sex (female/male), age (<50, 50–60, 61–70, 71–80,
>80 years), smoking status (nonsmoker, smoker, ex-smoker,
and missing), number of ARD diagnosed per person (1
benign, 2 or 3 benign, 4 or 5 benign/at least 1 malignant), and
source of exposure (environmental, household, and labor).
The number of ARD categories is based on a quantitative
approach according to a biological gradient presented as a
scale [23].
We categorised length of exposure according to the quar-
tiles of the study population [0–11.3), [11.3–20.9), [20.9–30.6),
(>=30.6 years).The smoking statuswas not fully collected and
a missing category was created for the statistical analysis. All
the above covariates were measured at the date of diagnosis.
We also recorded date of death, date(s) of any ARD events
diagnosed, and their clinical-related signs and symptoms.
2.6. Statistical Analysis. Descriptive statistics were used to
summarize the overall information. Categorical variables
were expressed as numbers (percentages) and continuous
variables as means (standard deviation, SD) and as medians
(interquartile ranges, IQR). Incidence rates (IR) of death
were calculated as person-years. For the numerator we used
number of deaths. The denominator was the sum of the
person-time contributed for each individual. Kaplan–Meier
life tables were used to calculate the quartiles of survival rates
across the strata of gender and age groups [24]. Log-rank and
Breslow tests were used for testing the equality of survival
curves among strata of these covariates. Competing risk
regression through a subdistribution hazard analysis [25] was
applied to estimate the association between risk factors and
the time to ARD-related death. The subdistribution hazard
ratio (SHR) reflects both the association of a covariate with
the event of interest and the contribution of the competing
events by actively maintaining individuals in the risk sets
(instead of being censored). Effects on the SHRcan be directly
translated to effects on the cumulative incidence function.
The SHR is the relative change in the hazard for one category
of a covariate compared with the reference category of the
corresponding covariate. A SHR > 1 indicates that those with
a higher value of a covariate will have a quicker time to event
in the study population. Similarly, a SHR< 1 indicates a longer
time to event for those with a higher value of a covariate
[26]. The SHR was estimated as the exponential function of
the regression coefficient, that is, exp (coefficient) through
the Stata command stcrreg. The follow-up time, in years,
was the time scale. The beginning of the survival time, when
a subject becomes at risk, was the onset of exposure. Each
subject’s follow-up time began after the date of diagnosis and
ended the date of any ARD death or censoring.Therefore, the
analysis was corrected for delayed entry, such that individuals
were considered under observation of ARD death only from
the date of diagnosis. Their entry into the risk sets was
delayed. There was a selection process taking place in that
only those subjects who were diagnosed were eligible to be
included in the study [27]. The latent period was defined as
the time between the date of the onset of exposure to asbestos
and the date of the diagnosis.
A competing risk event was considered when any other
causes of death (non-ARD) occurred without a preceding
outcome.The source and length of exposure have been judged
epidemiologically relevant variables, being included in the
final model. Additional analysis (not shown) was performed,
imputing tobacco missing values by multiple imputation
methods. The results were of a similar magnitude. We
checked for interactions but no significant ones were found.
The final model was adjusted by all significant, clinical, and
confounder variables. The proportional hazard assumptions
were assessed by adding the covariate by log-time interactions
to the model [25]. All results were expressed with 95%
confidence intervals (CIs) and statistical significance was set
at 𝑃 < 0.05 (two-tailed). The analyses were performed using
Stata/SE Version 12.1 (Stata Corp. LP, College Station, TX,
USA).
2.7. Ethical Conditions. Weconducted our research according
to the tenets established by the Declaration of Helsinki and
SpanishGoodResearch PracticeGuidelines.The study proto-
col was approved by the Clinical Research Ethics Committee
of the Institute-IDIAP Jordi Gol. Participants were given
written information andwere informed about implications of
the study prior to consenting to participate. Confidentiality
and anonymity were according to Spanish Personal Data
Protection Laws [28].
3. Results
Between the 544 cohort members, 73.2% of the subjects were
male, with amean age of 63.7 years (SD: 12.2).The 41.1% of the
total cohort suffered more than one benign ARD and 25.7%
had at least onemalignant ARD.Themost prevalent source of
exposure was from labor (73.5%) followed by environmental
exposure (15.3%). The median length of exposure was 21.0
years (IQR: 11.0–30.5) and the median length of latency was
41.6 years (IQR: 30.0–52.2) (Table 2). Among workers, 77.1%
had at least onemalignancy and, in the case of environmental
and household exposure, the proportion was 11.4%.
Pleural mesothelioma was diagnosed in 84 (15.4%)
patients; peritoneal mesothelioma in 15 (2.8%); and both
pleural and peritoneal mesotheliomas were found in 3 (0.6%)
patients. The remaining 38 malignancies were bronchopul-
monary neoplasms. All cases of peritoneal mesothelioma
weremen under 80 years, whose source of exposure was their
employment. The median survival time after the diagnosis
of pleural mesothelioma was 7.4 months and 8.4 months in
peritoneal.
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Table 2: Demographic and clinical characteristics at the date of
diagnosis of ARD, Barcelona (Spain), 1970–2006 (𝑁 = 544).
Characteristics Number (%)
Gender, male 398 (73.2)
Age (yrs); mean (SD) 63.7 (12.2)
Age groups
<50 82 (15.1)
50–59 139 (25.6)
60–69 134 (24.6)
70–79 140 (25.7)
>=80 48 (9.0)
Number of ARD
1 benign 180 (33.1)
2 or 3 benign 201 (36.9)
4 or 5 benign 23 (4.2)
>=1 malign 140 (25.7)
Source of exposure
Environmental 83 (15.3)
Household 61 (11.2)
Labor 400 (73.5)
Length of exposure (yrs); mean (SD); median
(IQR)
22.9 (15.8); 21.0
(11.0–30.5)
[0–11.3) 130 (23.9)
[11.3–20.9) 142 (26.1)
[20.9–30.6) 136 (25.0)
>=30.6 136 (25.0)
Period of latency (yrs); mean (SD); median (IQR) 41.0 (15.6); 41.6(30.0–52.2)
Smoking status
Nonsmoker 207 (38.1)
Smoker 153 (28.1)
Former 137 (25.2)
Missing 47 (8.6)
Age at onset of exposure of patient with outcomes
(yrs); mean (SD) 22.7 (11.7)
ARD death (𝑛 = 167) 26.0 (10.4)
Pleural mesothelioma diagnosis (𝑛 = 87) 23.2 (11.9)
Peritoneal mesothelioma diagnosis (𝑛 = 18) 27.4 (5.7)
ARD: asbestos-related disease; SD: standard deviation; IQR: interquartile
range.
Benign diseases diagnosed were pleural plaques (436),
pleural thickening (218), pulmonary effusions (58), rounded
atelectasis (25), and lung fibrosis (221). During the follow-
up (median: 4.1 years), ARD-related death was observed in
167 (30.7%) patients, 142 (26.1%) in men. Of these deaths,
78 (46.7%) were due to pleural mesothelioma, 15 (9%) to
peritoneal mesothelioma, 3 (1.8%) to both, 31 (18.5%) to
lung cancers, 1 (0.6%) to bronchopulmonary cancer, and 39
(23.4%) to at least one benign ARD (29 fibrosis, 10 pleural
plaques, 6 pleural thickening, 3 atelectasis, and 5 benign
pleural effusions).
Non-ARDdeathswere 41 (7.5%), of which 36 (87.8%)were
men and five (12.2%) were women. The incidence rate of
ARD-related death after the diagnosis was 3600 per 100,000
person-years and the incidence rate of ARD-related death
after the start of exposure was 620 per 100,000 person-
years (men: 760, women: 304). The median time of survival
from the start of exposure was 40.5 years; 40.9 years for
males and 35.5 years for females. Moreover, the difference in
survival curves from ARD between age groups was highly
significant (Log-rank/Breslow test: 𝑃 < 0.001).The incidence
rate of ARD mortality after the diagnosis increased with age
(Table 3).
In the adjusted analysis of ARD death, the model showed
evidence of nonproportional hazard in age and gender. Men
presented an increased and significantly higher risk than
women of dying from ARD, after 40 years from the start of
asbestos exposure. Patients aged between 60 and 69 years
had a higher risk of death from ARD in the first 30 years of
exposure, followed by the group 70–79 years (Table 4).
Former smokers were associated with a lower risk of
death from ARD-related diseases as compared with non-
smokers and people with household exposure were at higher
risk than those with labor, if we compared to those with
environmental exposure.
The ARD mortality risk rose sharply with the increasing
number of benign ARD, presenting the highest risk in
patients with at least one malignant ARD (HR = 128.3; 95%
IC: 3 (61.8–266.33)) (Table 5).
4. Discussion
4.1. Summarizing Key Results with Reference to Study Objec-
tives. Our study is the first to analyse the risk of death for all
ARD in a community. The main result is that nearly a third
of patients diagnosed with ARD die from it and more than
half due to some form of mesothelioma. Our research shows
that the following have a higher risk of dying from ARD: (a)
person between 60 and 80 years of age during the first 30
years of exposure to asbestos, (b) men with more than 40
years of exposure to this material, (c) people cohabiting with
an asbestos worker, and (d) an individual being diagnosed
with four or more ARD benign entities or at least one that
is malignant.
4.2. Comparisons. The high overall incidence of all ARD-
related deaths in a community, which increases with age,
is hardly comparable with current literature. This could be
because our study has estimated that rate from the time of
clinical diagnosis of ARD and not from the start of asbestos
exposure. On the other hand, the analysis considered all
deaths caused by ARD and not by any specific ARD.
Our study shows that men have a higher risk of death
from an ARD after 40 years of asbestos exposure, in agree-
mentwith other published studies [29]. It is likely that females
with occupational exposure could have worked in the factory
offices, so that their levels of asbestos exposure were lower
than men. Besides, older patients could be more likely to die
due to more comorbidity. In contrast, and similarly to other
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Table 3: Characteristics of ARD death overall and by gender and age group, Barcelona (Spain), 1970–2006 (𝑁 = 544).
Outcomes Number of events (%) Follow-up time (yrs)
∗;
mean (SD); median (IQR) Person-years at risk
Incidence rate/100000
person-years (95%
CI)
Log-rank/Breslow
test; 𝑃 values
Death from all ARD
Overall 167 (30.7) 8.5 (9.1); 4.1 (1.5–13.7) 4611.4 3600 (3092–4191)
Gender
Men 142 (26.1) 9.4 (9.8); 4.8 (1.6–16.2) 3746.2 3764 (3191–4439) 0.073/0.164
Women 25 (4.6%) 5.9 (6.4); 2.8 (1.3–9.0) 865.2 2890 (1952–4276)
Age groups
<50 30 (5.5%) 18.9 (10.4); 21.5 (12.2–28.5) 1551.4 1934 (1352–2766)
<0.001/<0.001
50–59 43 (7.9%) 11.9 (9.6); 10.0 (2.9–19.5) 1652.6 2602 (1930–3508)
60–69 40 (7.4%) 6.3 (6.4); 3.6 (1.4–9.8) 846.4 4726 (3466–6443)
70–79 42 (7.7%) 3.2 (3.2); 2.4 (0.9–4.6) 452.3 9065 (6674–12311)
>=80 12 (2.2%) 2.2 (1.9); 1.8 (0.8–2.8) 108.6 11045 (6273–19449)
ARD: asbestos-related diseases; SD: standard deviation; IQR: interquartile range; CI: confidence interval. ∗The follow-up time for death from all ARD was
defined as the number of years from the date of diagnosis to the date of any ARD-related-death or to censoring.
studies in women exposed to asbestos from environmental
[30] or household exposure [31, 32], our research shows that
women have a higher risk of death during the first 40 years
of exposure compared to men. However, this risk is not
statistically significant.
In our research, the proportion of deaths is much higher
in men than in women during the same period (male: 44.7%
versus female: 20.5%) as shown by Helland et al. [33]. It is
not possible to rule out underreporting in all ARD entities,
not only in the first 40 years, but also throughout the study
period, which would produce a certain underestimation of
the risk of death from ARD, especially in men.
The greatest risk of dying from ARD in the household
group similarly observed by Ferrante et al. [32] can be
explained by the healthy survival effect.This is due to the long
duration of exposure under conditions of lower susceptibility
to ARD in patients who have survived. This risk could be
higher since forms of ARD other than mesothelioma are
difficult to detect in nonoccupational exposure.
It is difficult to compare our data on the benign fraction
of ARD in Spain since the publication of the series of these
entities in the occupational field of asbestos should have been
more thorough. Notably between 1990 and 2010 only 535
cases of a single labor benign ARD affecting 98% ofmenwere
declared [6].
Benign ARD is a common occurring abnormality in peo-
ple exposed to asbestos and is not a precursor of malignant
ARD [29, 34] and our study coincides with this [19]. In spite
of this benignity [29, 34] our cutting-edge research shows
that there is an increased risk of dying from an accumulated
number of benign entities (HR > 10 for 4 or 5 benign entities)
or having at least one that is malignant (HR = 128.3).
Regarding malignant ARD, it is known that the median
survival time is a good point estimate of mortality from ARD
[33, 35, 36]. Our data on this median is similar to those
reported by other authors; Lee and colleagues put it at 6
months [35] other researchers at 9.3 months in Norway [33]
and 18 months in Turkey [36].
4.3. Strengths of the Study. The cohort in the present study
is unique because it includes an overall and a well-defined
population in an area with high and long asbestos exposure
with a similar latent period to the asbestos literature [32].
The completeness of the data was checked centrally and the
outcomes were ascertained and confirmed after a review of
medical records. Moreover, the concordance rate between
our underlying causes of death and those from the official
mortality register data bank was high.
We adjusted HR for competing risks of death to avoid
overestimation of the risk of ARD events, considering that the
time at risk is long and competing risks of death from other
causes are high. Moreover, the subdistribution of hazard is
an appropriate measure for predicting an individual’s risk
for an outcome or allocating resources. This method models
the effect of covariates on the event by incorporating the
association between covariates and the event of interest as
well as the competing event which influences the risk set [26].
4.4. Limitations of the Study. In the absence of official
measures of occupational and environmental asbestos and
general data on the overall ARD morbidity and mortality
in Spain [6], the duration of exposure has been employed
as a surrogate quantitative exposure measure. We have not
considered neither the intensity of exposure that could have
varied across individuals [30] and time periods nor the recall
bias of past exposures that could have caused biased estimates
of association [37]. We have not quantified the effect of
asbestos waste sites in an area free of naturally occurring
asbestos [38, 39], which holds the highest Spanish mortality
rate from mesothelioma [40]. The information related to any
other ARD deaths (benign or malign) remains unknown.
We have not taken into account variables such as physical
examination interval or clinical treatment due to irregular
follow-up and lack of medical record information.
The diagnosis of ARD can lead to misclassification errors
because pleural plaques can be valued as mimicking shadows
[41], due to a lack of sensitivity in chest radiographs [42];
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Table 4: Adjusted effects of nonproportional risk factors on subhazard from ARD death, Barcelona (Spain), 1970–2006 (𝑁 = 544).
Survival time (yrs)
Sex
SHR
(95% CI)&
(Ref: female)
𝑃 value Age groups (Ref: <50 yrs) SHR (95% IC)& 𝑃 value
15 0.34 (0.09–1.29) 0.114
50–59 2.01 (0.42–9.66) 0.381
60–69 37,17 (6.69–206.58) 0.000
70–79 11.02 (2.00–60.62) 0.006
>=80 5.85 (0.41–83.47) 0.193
20 0.43 (0.13–1.36) 0.149
50–59 1.61 (0.43–6.00) 0.477
60–69 20.10 (4.84–83.43) <0.001
70–79 8.26 (1.95–35.04) 0.004
>=80 5.07 (0.51–50.78) 0.167
30 0.67 (0.30–1.53) 0.342
50–59 1.03 (0.43–2.49) 0.947
60–69 5.88 (2.39–14.47) <0.001
70–79 4.64 (1.80–12.00) 0.002
>=80 3.82 (0.75–19.39) 0.106
40 1.05 (0.60–1.84) 0.852
50–59 0.66 (0.32–1.35) 0.253
60–69 1.72 (0.90–3.29) 0.102
70–79 2.61 (1.48–4.60) 0.001
>=80 2.87 (1.00–8.25) 0.050
50 1.66 (1.02–2.69) 0.042
50–59 0.42 (0.16–1.10) 0.078
60–69 0.50 (0.20–1.27) 0.144
70–79 1.47 (0.82–2.64) 0.202
>=80 2.16 (0.92–5.07) 0.077
60 2.60 (1.32–5.11) 0.006
50–59 — —
60–69 0.15 (0.03–0.63) 0.010
70–79 0.82 (0.31–2.21) 0.700
>=80 1.62 (0.48–5.48) 0.434
70 4.08 (1.53–10.92) 0.005
50–59 — —
60–69 — —
70–79 0.46 (0.10–2.04) 0.309
>=80 1.22 (0.19–7.66) 0.830
80 6.41 (1.69–24.26) 0.006
50–59 — —
60–69 — —
70–79 — —
>=80 0.69 (0.07–11.54) 0.948
Note. Ref: reference; CI: confidence interval; SHR: subdistribution hazard ratio. &Cox proportional hazard model, accounting for other causes of death as
competing risks. Robust standard errors. All SHRs were adjusted for sex, age groups, smoking status, source of exposure, length of exposure, number of ARD,
and sex ∗ time and age groups ∗ time interactions.
pulmonary fibrosis shows a clear separation between its
clinicoradiology and histopathology [9] and the three his-
tological types of pleural mesothelioma may have different
clinical outcomes [43]. Underestimation of exposure must
be considered due to the clearance of asbestos in the body
and the high cost of pathological anatomy techniques for
the detection of asbestos bodies. It should be noted in the
interpretation of results that the definition of ARD includes
a heterogeneous group of malignant and benign diseases.
Moreover, the existing confidentiality in the Spanish labor
regulation for people working with asbestos, the usual refusal
to participate in such studies, the healthy survivor effect, and
a misclassification error in the cause of death [16, 32] could
have all caused a selection bias. These biases may underesti-
mate the risk of death from all ARD. Other etiologic factors
such as the genetic profile and the different susceptibility to
asbestos exposure have not been studied in this research.
The aggregate analysis of ARD deaths using competing
risks allows a better approximation to the population estimate
of the risk from exposure to asbestos. In spite of this, its
result can only be generalizable for similar competing risk
rate communities [26].
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Table 5: Adjusted effects of proportional risk factors on subhazard
from ARD death, Barcelona (Spain), 1970–2006 (𝑁 = 544).
Predictors SHR (95% CI)& 𝑃 value
Smoking status
Nonsmoker (Ref.) 1
0.003Smoker 1.01 (0.59–1.71)
Former 0.56 (0.35–0.87)
Missing 1.79 (0.98–3.26)
Source of exposure
Environmental (Ref.) 1
0.074Household 1.98 (1.07–3.64)
Labor 1.22 (0.68–2.19)
Length of exposure (yrs)
[0–11.3) (Ref.) 1
0.935[11.3–20.9) 1.17 (0.70–1.97)
[20.9–30.6) 1.20 (0.63–2.26)
>=30.6 1.18 (0.58–2.42)
Number of ARD
1 benign (Ref.) 1
<0.0012 or 3 benign 1.94 (0.86–4.38)
4 or 5 benign 10.28 (3.36–31.43)
At least 1 malign 128.30 (61.82–266.25)
Note. Ref: reference; SHR: subdistribution hazard ratio; CI: confidence
interval; &Cox proportional hazard model, accounting for other causes of
death as competing risks. Robust standard errors. All SHRs were adjusted for
the other covariates in the table and sex, age groups, and sex ∗ time and age
groups ∗ time interactions.
4.5. Overall Interpretation and Implications for Research,
Practice, and Prevention. Our research shows the effects of
prolonged exposure to asbestos which resulted in a high
incidence rate of ARD mortality. This kind of exposure and
outcome can only be produced by inadequate preventive
and protective measures against asbestos and a permissive
legislation used andmarketed until 2001.The underreporting
of benign asbestos occupationalmorbidity and the accumula-
tion of benignARDmortality could have contributed to these
results. It is necessary to develop a preventive approach to
the community [44], create a registry of people exposed to
asbestos and ARD cases, and improve the clinical follow-up
of all ARD patients.
Globally, the annual market demand for asbestos exceeds
2,000,000MT [4, 45] and several authors have predicted a
revival of ARD in the coming decades, especially in low-
income countries [2, 9] despite theworldwideARDpandemic
[4].Undoubtedly, the absence of an international government
health platform dedicated to the study and control of the
effects of asbestos removes the possibility of eradicating death
by ARD [46, 47].
4.6. In Summary. The harmful effects of a community per-
manently exposed to asbestos reflect that age, sex, nonoccu-
pational exposure, cumulated benignARD, and singlemalign
pathology account as risk factors for a high risk of death
from ARD. A clinical and preventive approach should be
implemented in the community in order to control the effects
of the asbestos.
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